Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

Abstract Background In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) bu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of antimicrobial chemotherapy 2021-02, Vol.76 (3), p.738-742
Hauptverfasser:	Rial-Crestelo, David, de Miguel, Rosa, Montejano, Rocío, Dominguez-Dominguez, Lourdes, Aranguren-Rivas, Paula, Esteban-Cantos, Andrés, Bisbal, Otilia, Santacreu-Guerrero, Mireia, Garcia-Alvarez, Mónica, Alejos, Belén, Hernando, Asunción, Bermejo-Plaza, Laura, Cadiñanos, Julen, Mayoral, Mario, Castro, Juan Miguel, Moreno, Victoria, Martin-Carbonero, Luz, Delgado, Rafael, Rubio, Rafael, Pulido, Federico, Arribas, José Ramón
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-HIV Agents - therapeutic use Drug Therapy, Combination Heterocyclic Compounds, 3-Ring HIV Infections - drug therapy HIV-1 - genetics Humans Lamivudine - therapeutic use Oxazines Pilot Projects Piperazines - therapeutic use Pyridones Retrospective Studies Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!